JP2023511963A5 - - Google Patents

Info

Publication number
JP2023511963A5
JP2023511963A5 JP2022545037A JP2022545037A JP2023511963A5 JP 2023511963 A5 JP2023511963 A5 JP 2023511963A5 JP 2022545037 A JP2022545037 A JP 2022545037A JP 2022545037 A JP2022545037 A JP 2022545037A JP 2023511963 A5 JP2023511963 A5 JP 2023511963A5
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
seq
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022545037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511963A (ja
Filing date
Publication date
Priority claimed from KR1020200009565A external-priority patent/KR20210095781A/ko
Application filed filed Critical
Publication of JP2023511963A publication Critical patent/JP2023511963A/ja
Publication of JP2023511963A5 publication Critical patent/JP2023511963A5/ja
Pending legal-status Critical Current

Links

JP2022545037A 2020-01-24 2021-01-23 多重特異性抗体、それを含む組成物、およびベクター、ならびにそれらの使用 Pending JP2023511963A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR1020200009565A KR20210095781A (ko) 2020-01-24 2020-01-24 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR10-2020-0009565 2020-01-24
US16/878,255 US20210230285A1 (en) 2020-01-24 2020-05-19 Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
US16/878,255 2020-05-19
PCT/IB2021/050519 WO2021149015A1 (en) 2020-01-24 2021-01-23 Multispecific antibodies, compositions comprising the same, and vectors and uses thereof

Publications (2)

Publication Number Publication Date
JP2023511963A JP2023511963A (ja) 2023-03-23
JP2023511963A5 true JP2023511963A5 (enExample) 2024-01-25

Family

ID=76969825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022545037A Pending JP2023511963A (ja) 2020-01-24 2021-01-23 多重特異性抗体、それを含む組成物、およびベクター、ならびにそれらの使用

Country Status (17)

Country Link
US (3) US20210230285A1 (enExample)
EP (1) EP4093764A4 (enExample)
JP (1) JP2023511963A (enExample)
KR (2) KR20210095781A (enExample)
CN (1) CN116113642A (enExample)
AU (1) AU2021211241A1 (enExample)
CA (1) CA3165029A1 (enExample)
CL (2) CL2022001993A1 (enExample)
CO (1) CO2022011885A2 (enExample)
CR (1) CR20220415A (enExample)
DO (1) DOP2022000150A (enExample)
EC (1) ECSP22065625A (enExample)
IL (1) IL294917A (enExample)
JO (1) JOP20220171A1 (enExample)
MX (1) MX2022009150A (enExample)
PH (1) PH12022551828A1 (enExample)
WO (1) WO2021149015A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
KR20210095781A (ko) * 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
JP2024536320A (ja) * 2021-10-04 2024-10-04 アストラゼネカ・アクチエボラーグ ループスの処置
CN114149508B (zh) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 一种结合cd40l的融合蛋白及其应用
WO2024039238A1 (ko) * 2022-08-19 2024-02-22 주식회사 프로앱텍 단일쇄 가변 단편의 변이 단백질
CN121532422A (zh) 2023-11-28 2026-02-13 H.隆德贝克有限公司 用于在治疗甲状腺眼病中使用的融合蛋白

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
CN1247472A (zh) 1997-01-10 2000-03-15 拜奥根有限公司 用抗cd40l化合物治疗狼疮性肾炎
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
BR9809641A (pt) 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
CN1261285A (zh) 1997-06-20 2000-07-26 拜奥根有限公司 治疗性蛋白抑制剂综合症的cd154阻断治疗
SK180299A3 (en) 1997-06-20 2000-06-12 Biogen Inc Cd40:cd154 blockade therapy for pancreatic islet tissue transplantation
DE60037822D1 (de) 1999-10-22 2008-03-06 Biogen Idec Inc Verwendung eines cd40:cd154 bindungs-unterbrechers zur behandlung immunologischer komplikationen des auges
WO2001062907A1 (fr) 2000-02-22 2001-08-30 Medical & Biological Laboratories Co., Ltd. Bibliotheque d'anticorps
GB0019820D0 (en) 2000-08-12 2000-09-27 Koninkl Philips Electronics Nv Selective delivery of data
FI112501B (fi) 2001-05-18 2003-12-15 Valtion Teknillinen Heveiiniä sitovat monoklonaaliset vasta-aineet
CA2418808A1 (en) 2001-06-12 2002-12-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor viii antibody
EP1439192A1 (en) 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004254080A1 (en) 2003-07-03 2005-01-13 Unicrop Ltd. Novel rubisco promoters and uses thereof
CN101031588A (zh) 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物,融合物和结合物
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
AU2005334481A1 (en) 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
MX2007003907A (es) 2004-10-05 2007-05-21 Genentech Inc Agentes terapeuticos con toxicidad reducida.
RU2411957C2 (ru) 2004-12-02 2011-02-20 Домантис Лимитед Способы лечения респираторного заболевания с применением антагонистов рецептора интерлейкина-1 типа 1
US8709219B2 (en) 2005-03-10 2014-04-29 Panasonic Corporation Structured diamond tool made by focused ion beam nanomachining
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JP4940013B2 (ja) 2006-07-31 2012-05-30 富士通株式会社 半導体装置に対する同時動作信号ノイズ見積り方法、およびプログラム
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
ME00832B (me) 2007-03-22 2012-03-20 Ucb Biopharma Sprl Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
WO2008127655A1 (en) 2007-04-13 2008-10-23 Biogen Idec Ma Inc. Anti-alpha 6 beta 4 integrin antibodies and uses therof
AU2008261042A1 (en) 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of CH1 domain
US8846867B2 (en) 2007-06-26 2014-09-30 The Trustees Of The University Of Pennsylvania Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20110033476A1 (en) 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2604279A1 (en) 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
JP2012502649A (ja) 2008-09-19 2012-02-02 メディミューン,エルエルシー Cd105を対象とする標的結合剤およびその使用
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
EP2364326B1 (en) 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
EP2432803A2 (en) 2009-05-20 2012-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011019932A2 (en) 2009-08-14 2011-02-17 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2896632B1 (en) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
US20120213771A1 (en) 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
EP2663334A4 (en) 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
WO2012112489A2 (en) 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
BR112013023576A2 (pt) 2011-03-15 2016-12-06 Theraclone Sciences Inc composições e métodos para a terapia e diagnóstico de influenza
HUE038848T2 (hu) 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
JP5413432B2 (ja) 2011-10-20 2014-02-12 コニカミノルタ株式会社 画像形成装置
HRP20201370T1 (hr) 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
ES2842201T3 (es) 2012-02-23 2021-07-13 Daiichi Sankyo Europe Gmbh Inhibidor de HER3 para modulación de radiosensibilidad
MX353278B (es) 2012-03-06 2018-01-05 Regeneron Pharma Raton con cadena ligera comun.
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
JP2015520172A (ja) 2012-05-31 2015-07-16 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. Dll−4に結合する抗原結合蛋白質
MX2014014891A (es) 2012-06-05 2015-06-17 Regeneron Pharma Metodos para hacer anticuerpos biespecificos completamente humanos usando una cadena ligera comun.
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
BR112015010240A2 (pt) 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
HK1218550A1 (zh) 2013-03-13 2017-02-24 Regeneron Pharmaceuticals, Inc. 常見輕鏈小鼠
EP4545567A3 (en) 2013-03-13 2025-08-13 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2968985A2 (en) 2013-03-15 2016-01-20 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
JP2016519688A (ja) 2013-04-22 2016-07-07 セラクローン サイエンシーズ, インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
CA2916259C (en) 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
BR112016004355A2 (pt) 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
WO2016135239A1 (en) * 2015-02-25 2016-09-01 Biotecnol Limited Fusion protein comprising three binding domains to her2
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016164468A2 (en) 2015-04-07 2016-10-13 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to adamts13 and uses thereof
US9708412B2 (en) * 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
TW201702272A (zh) 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Prame肽專一性類t細胞受體抗體
US11359010B2 (en) 2015-07-13 2022-06-14 UNIVERSITé LAVAL Humanized anti-S100A9 antibody and uses thereof
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗angptl8抗體及其用途
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗lag3抗體及其用途
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
EP3430058A4 (en) * 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
US20190224339A1 (en) 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN113831407B (zh) 2016-05-20 2024-06-11 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
CN109563170B (zh) 2016-06-10 2023-10-13 瑞泽恩制药公司 抗gitr抗体及其用途
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018009732A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
EP3489262A4 (en) 2016-07-19 2020-07-08 Ibentrus, Inc. BISPECIFIC PROTEINS AND PROCESSES FOR THEIR PREPARATION
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗muc16(ムチン16)抗体
WO2018075621A1 (en) 2016-10-19 2018-04-26 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
LT3538554T (lt) 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
EA201991203A1 (ru) 2016-11-17 2019-10-31 Способы лечения ожирения антителами к angptl8
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
KR102840867B1 (ko) 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
KR20200018781A (ko) * 2017-06-19 2020-02-20 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 반감기 연장 폴리펩티드를 갖는 융합 단백질
WO2019201866A1 (en) 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein
JP2022540187A (ja) 2019-07-08 2022-09-14 プロジェン・カンパニー・リミテッド 新規融合タンパク質及びその用途
KR20210095781A (ko) * 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Similar Documents

Publication Publication Date Title
JP2023511963A5 (enExample)
DK2744931T3 (en) SOLUBLE POLYPEPTIDES
JP2010534478A5 (enExample)
JP2019533719A5 (enExample)
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
JP2023548443A5 (enExample)
JP2021530244A5 (enExample)
JP2018526981A5 (enExample)
JP2022540083A5 (enExample)
JP2024532489A5 (enExample)
JP2022553922A5 (enExample)
JP2023549537A5 (enExample)
JP2021516951A5 (enExample)
JP2024001073A5 (enExample)
JP2024504390A5 (enExample)
JP2010509931A5 (enExample)
JP2019507580A5 (enExample)
JP2023509390A5 (enExample)
JP2019505166A5 (enExample)
JP2021512159A5 (enExample)
JP2020515277A5 (enExample)
TW201632547A (zh) 一種由噬菌體表現之單鏈變異片段抗體庫
JP2023524811A5 (enExample)
JP2022513050A5 (enExample)
JP2018533937A5 (enExample)